Skip to content

Study · Randomized controlled trial · 2024

12 results

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.

Mashayekhi M, Nian H, Mayfield D, Devin JK, Gamboa JL, Yu C, Silver HJ, Niswender K, Luther JM, Brown NJ

Diabetes1 Jan 2024Cited by 54 (Europe PMC)

PMID37874653 (opens in a new tab)PMCIDPMC10784656 (opens in a new tab)DOI10.2337/db23-0356 (opens in a new tab)PepBankPUB-37874653
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide caused weight loss over 14 weeks, as did a hypocaloric diet but not sitagliptin.

    In plain wordsIn people with obesity and prediabetes, liraglutide led to weight loss over 14 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide and diet, but not sitagliptin, caused weight loss.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide improved insulin sensitivity by HOMA-IR after 2 weeks, before weight loss.

    In plain wordsIn people with obesity and prediabetes, liraglutide improved insulin sensitivity within 2 weeks, before weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity by HOMA-IR after 2 weeks
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide improved insulin sensitivity by the updated HOMA model (HOMA2) after 2 weeks, before weight loss.

    In plain wordsIn people with obesity and prediabetes, liraglutide improved insulin sensitivity within 2 weeks, before weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity by HOMA2 after 2 weeks
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide improved insulin sensitivity by the Matsuda index after 2 weeks, before weight loss.

    In plain wordsIn people with obesity and prediabetes, liraglutide improved insulin sensitivity within 2 weeks, before weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity by Matsuda index after 2 weeks
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide decreased fasting glucose levels.

    In plain wordsIn people with obesity and prediabetes, liraglutide lowered fasting blood glucose.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide decreased postprandial glucose levels.

    In plain wordsIn people with obesity and prediabetes, liraglutide lowered blood glucose after meals.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide decreased insulin levels.

    In plain wordsIn people with obesity and prediabetes, liraglutide lowered insulin levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin levels
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide decreased C-peptide levels.

    In plain wordsIn people with obesity and prediabetes, liraglutide lowered C-peptide levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseC-peptide levels
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In individuals with obesity and prediabetes, liraglutide decreased fasting glucagon levels.

    In plain wordsIn people with obesity and prediabetes, liraglutide lowered fasting glucagon levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucagon
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels.
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  10. 10HumanRandomized controlled trialMechanism

    In individuals with obesity and prediabetes on liraglutide, acute GLP-1R antagonism with exendin(9-39) increased the Matsuda index.

    In plain wordsIn people with obesity and prediabetes on liraglutide, blocking the GLP-1 receptor raised the Matsuda index, a measure of insulin sensitivity.

    Peptide
    Liraglutide
    Outcome
    IncreaseMatsuda index during GLP-1R antagonism with exendin(9-39)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    increased the Matsuda index and fasting glucagon level during liraglutide treatment
    2 context sentences
    Summary · context
    Liraglutide improved insulin sensitivity and decreased fasting and postprandial glucose prior to weight loss, and these benefits were reversed by exendin(9-39).
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  11. 11HumanRandomized controlled trialMechanism

    In individuals with obesity and prediabetes on liraglutide, acute GLP-1R antagonism with exendin(9-39) increased fasting glucagon levels.

    In plain wordsIn people with obesity and prediabetes on liraglutide, blocking the GLP-1 receptor raised fasting glucagon levels.

    Peptide
    Liraglutide
    Outcome
    Not applicableFasting glucagon during GLP-1R antagonism with exendin(9-39)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    increased the Matsuda index and fasting glucagon level during liraglutide treatment
    1 context sentence
    Summary · context
    Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.
  12. 12HumanRandomized controlled trialMechanism

    In individuals with obesity and prediabetes, acute GLP-1R antagonism with exendin(9-39) increased glucose levels in all groups, including during liraglutide treatment.

    In plain wordsIn people with obesity and prediabetes, blocking the GLP-1 receptor raised blood glucose in all groups, including those on liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucose levels during GLP-1R antagonism with exendin(9-39)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Acute GLP-1R antagonism increased glucose levels in all groups, increased the Matsuda index and fasting glucagon level during liraglutide treatment, and increased endogenous GLP-1 values during liraglutide and sitagliptin treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.